Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Moderna (MRNA) Surges 3.2%: Is This an Indication of Further Gains?

The European regulator's advisory panel on Thursday recommended authorizing Moderna's COVID-19 vaccine targeting the Omicron XBB.1.5 subvariant.

EU regulator panel recommends authorizing Moderna's updated COVID shot

The positive opinion follows the recommendation from regulators and global public health bodies to develop monovalent XBB.1.5 COVID-19 vaccines for autumn/winter 2023 vaccination campaigns Clinical trial data from research assay confirmed Moderna's updated COVID-19 vaccine showed an 8.7 to 11-fold increase in neutralizing antibodies against circulating variants, including BA.2.86, EG.5, and FL.1.5.1 variants CAMBRIDGE, MA / ACCESSWIRE / September 14, 2023 / Moderna, Inc. (Nasdaq:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for Spikevax, its updated COVID-19 vaccine containing spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. Following the CHMP's positive opinion, the European Commission will make an authorization decision on the use of Moderna's updated COVID-19 vaccine for autumn/winter 2023.

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's Updated Covid-19 Vaccine in The European Union

Novavax

BA.2.86 is a new COVID variant health officials have been eyeing lately. But recent reports suggest that it may not be all that concerning.

Why COVID Vaccine Demand Might Not Be That Strong

American Superconductor

BlackBerry

Lithium Americas Corp

Cassava Sciences Inc

Super Micro Computer

SoFi Technologies

Given the horrendous performance of meme kings like AMC Entertainment (NYSE: AMC ) and GameStop (NYSE: GME ) lately, searching for the best meme stocks may be the last thing on your mind right now. In fact, considering GME's continued declines, and AMC's capitulation in recent weeks, you may think that the meme stock phenomenon has completely gone the way of the dodo.

The 7 Best Meme Stocks to Buy Now: September 2023

Moderna, Inc. (NASDAQ:MRNA ) R&D Day and Business Updates September 13, 2023 1:00 PM ET Company Participants Stephane Bancel - CEO Stephen Hoge - President Jackie Miller - SVP, Therapeutic Area Head, Infectious Diseases Darin Edwards - Executive Director, COVID Vaccines Program Leader Raffael Nachbagauer - Program Leader for Influenza Vaccines Arpa Garay - Chief Commercial Officer Kyle Holen - Head of Development, Oncology and Therapeutics Michelle Nguyen - Director of Marketing James Mock - CFO Conference Call Participants Geoff Meacham - BofA Michael Yee - Jefferies Evan Wang - Guggenheim Salveen Richter - Goldman Sachs Gina Wang - Barclays Tyler Van Buren - TD Cowen Hartaj Singh - Oppenheimer Steve Chesney - Redburn Atlantic Stephane Bancel Thank you for those joining us here and thank you for those joining us online today. Before I start, let me just remind you that we'll be making forward-looking statements, and of course, Investing in Moderna entails risk.

Moderna, Inc. (MRNA) R&D Day and Business Updates (Transcript)

Stephane Bancel told Barron's the company won't be defined by its Covic-19 vaccine even as it uses the same technology to develop other vaccines.

'This Is Not a Covid Vaccine Company,' Moderna CEO Says

Moderna (MRNA) was one of the best-performing stock in the S&P 500 as the vaccine maker reported its experimental flu shot met its primary endpoint in a Phase 3 trial.

Moderna Reports Successful Trial of Flu Vaccine, Plans More Treatments Ahead

Shares of Moderna (NASDAQ: MRNA ) — which rose to prominence with its Covid-19 vaccine — are jumping on Wednesday. Disclosing encouraging results for its mRNA-based flu shot, the biotech company may have the opportunity to pivot beyond its Covid vaccine.

Flu Vaccine Results Give Moderna (MRNA) Stock a Shot in the Arm

Moderna Inc  (NASDAQ:MRNA) stock is up 6.5% to trade at $112.09 at last check, after a late-stage trial of its flu vaccine induced a stronger immune response against all four A and B strains of the virus in comparison to other flu shots.

Options Bulls Blast Moderna Stock on Vaccine Tailwinds

The CEO of Moderna Inc. (NASDAQ: MRNA) showed optimism for the company in a recent interview for Squawk Box on CNBC, foreseeing between $6 billion to $8 billion in sales in 2023, as their COVID-19 booster got approved by the FDA on September 11.

Moderna CEO eyes $8 billion in sales for 2023: ‘Covid is not going away'

Pfizer

Updated Covid vaccines from Pfizer and Moderna will soon be administered at pharmacies, and many other locations across the U.S.

New Covid vaccines could reach Americans as soon as Thursday – here's what you need to know

Moderna compared the flu vaccine, dubbed mRNA-1010, to a currently approved seasonal flu vaccine from GlaxoSmithKline called Fluarix.

Moderna says flu vaccine showed promising results in phase three trial, paving path to approval

Advance Auto Parts

Bio-Rad Laboratories

Catalent

Dollar General

Estee Lauder

Enphase Energy

Etsy

KeyCorp

MarketAxess Holdings

Mosaic

Newell Brands

Paramount Global

Insulet

ResMed

SolarEdge Technologies

Sealed Air

Walgreens

Window dressing is a deceitful practice where mutual funds and other large institutions buy high-flying stocks and sell off the losing ones just before the end of a quarter, when many funds must report their holdings.

These Stocks Could Face Selling Pressure Soon

Moderna expects to launch up to 15 new products over the next five years 'addressing high unmet needs.'

Moderna Stock Rises on Positive Results From Flu Vaccine

Moderna on Wednesday announced it was scaling down manufacturing of its COVID-19 vaccine, an updated version of which was approved this week by U.S. regulators, to align with lower post-pandemic demand and help the company sooner hit its target of 75% to 80% gross margin growth.

Moderna to scale down manufacturing of COVID vaccine

As it looks to expand its horizons beyond COVID-19 vaccines, Moderna Inc. MRNA, -0.53% on Wednesday released positive results from a late-stage trial of an mRNA flu vaccine and signaled progress across a range of investigational treatments for cancer and rare, latent and infectious diseases.

Moderna aims to prove it's ‘more than a COVID company'

Moderna said Wednesday its flu shot outperformed broadly used vaccines from Sanofi and GSK. The results could bolster Moderna stock.

Moderna Stock Has Been Beaten Up; Why The CFO Says Its Story Is 'Misunderstood'

Company's flu vaccine, mRNA-1010, met its primary endpoint in Phase 3 trial; separate Phase 1/2 data demonstrated higher HAI titers than Fluzone HD Vaccine pipeline advancing rapidly with Company announcing the completion of RSV BLA filing (mRNA-1345), completion of adult enrollment in the Phase 3 trial of mRNA-1647, a first-in-class vaccine against CMV, and the Phase 3 trial of mRNA-1283, a next-generation COVID-19 vaccine With its partner Merck, the Company plans to begin a second Phase 3 trial of mRNA-4157, its individualized neoantigen therapy (INT), in combination with Keytruda®, for non-small cell lung cancer later this year; updated efficacy follow-up from the ongoing Phase 2 study in adjuvant melanoma expected in Q4 With positive clinical data announced in mRNA-3705, a treatment for methylmalonic acidemia, the Company has three chronic rare disease medicines that have demonstrated potential for clinical benefit in patients Over the next five years, the Company expects to launch up to 15 new products addressing high unmet needs, to bring up to 50 new candidates into clinical trials and to continue expanding the field of mRNA into new applications CAMBRIDGE, MA / ACCESSWIRE / September 13, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced business and clinical updates across its franchises and introduced several new development programs at the Company's annual R&D Day. "Our mRNA platform is working.

Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease

Amgen

It's been a difficult time for biotechnology stocks. After a boom during the Covid-19 pandemic, the entire sector appears to have been abandoned by investors.

The 3 Most Undervalued Biotech Stocks to Buy in September 2023

CDC Director Mandy Cohen still has to sign off on the panel's recommendation before the new Pfizer and Moderna Covid vaccines become available nationwide.

CDC advisors recommend updated Covid vaccines for all Americans ages 6 months and up

Advisers to the Centers for Disease Control and Prevention voted Tuesday to recommend updated COVID-19 vaccines for people 6 months of age and older. The 13-to-1 vote comes just one day after the U.S. Food and Drug Administration approved the updated shots from Moderna Inc. MRNA, -0.53% and Pfizer Inc. PFE, +0.65%.

CDC advisers recommend updated COVID shots for people 6 months of age and older

Moderna, Inc. (NASDAQ:MRNA ) Morgan Stanley 21st Annual Global Healthcare Conference September 12, 2023 12:15 PM ET Company Participants Stephane Bancel - CEO Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Great. Well, good afternoon, everybody.

Moderna, Inc. (MRNA) Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)

The deal will combine Moderna (MRNA) and Immatics' (IMTX) proprietary platforms to develop innovative immunotherapies for cancer.

Moderna (MRNA), Immatics Ink Deal to Develop New Cancer Therapies

Canadian health officials on Tuesday authorized Moderna's COVID-19 vaccine targeting the Omicron subvariant, urging all Canadians over the age of six months to get fresh inoculations as the nation sees an uptick in infections.

News for Moderna Stock (MRNA)